Loading…
← CockpitCompetitor Analysis › PGHL.NS Procter & Gamble Health Ltd.Open in the cockpit ↗

Procter & Gamble Health Ltd.PGHL.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Pharmaceuticals: Major
Momentum neutral 56
Mkt cap
$979M
US dollars, full cap
Free float
48%
of shares outstanding
$/day
$909,111
20-day average traded
Fwd P/E
24.5×
forward earnings
ROIC−WACC
+86.5 pp
WACC 9.9%
Hurdle
-4 pp
Req g minus delivered
Next earnings
105 days
3 Mar 2027
Close · INR₹5,505
1D+0.7%
1W-4.7%
1M+7.2%
3M-5.7%
6M+3.1%
YTD-3.5%
1Y-6.6%
ATR %3.6%
Beta0.46
52w lowhigh21.1% off high

What Procter & Gamble Health does

Employees: 1,500

Procter & Gamble Health at a glance

Size Procter & Gamble Health (PGHL.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $979M, the 611th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹5,505 on 18 Nov 2026.

Performance Over six months the shares gained 3.1%, against -14.5% for the median peer and +3.8% for the India market (cap-weighted) — 6th highest of 21 in its peer set.

Growth Revenue grew 13.0% over the last twelve months (peer median +5.7%); the operating margin is 30.8% (peer median 10.5%).

Valuation It trades at 24.5× forward earnings against a peer median of 19.8× (5th most expensive of 14).

Price implies For today's price to make sense, revenue must grow about 6% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is -4 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 86.5 points above its cost of capital (9.9% WACC).

Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).

Relative performance

10012021 May 202621 Aug 202618 Nov 2026PGHL.NS 103Peer median 90
Six months, rebased to 100: Procter & Gamble Health against the median of its 20 peers (local-currency closes).

Procter & Gamble Health financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹14.1B₹14.1B₹12.5B₹12.3B₹11.1B
Revenue growth—+13%+1%+11%—
Gross profit₹7.97B₹7.03B₹6.12B₹5.64B₹5.08B
EBITDA₹4.57B₹4.64B₹4.32B₹3.29B₹2.71B
Net income₹3.27B₹3.27B₹3.13B₹2.29B₹1.93B
Free cash flown/a₹3.33B₹1.67B₹2.08B₹1.41B
Capital expendituren/a₹155M₹85.6M₹425M₹379M
Total debt₹72.1M₹92.9M₹76.2M₹120M₹28.3M

Quarterly statements and history in the cockpit →

Procter & Gamble Health competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%+50%-20%0%+20%SPTX600129688382AARTIPHARM456560055768875930029468871060511668809120054887603538300702002437600422300497PGHL.NS6-month return →1-month return →
Up and to the right = strong over both horizons. Procter & Gamble Health is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%20×40×60×60012945656005573002946887106051162005STAR000650603538300702300497PGHL.NSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Procter & Gamble Health is the large dot.

Capital: growth delivered against growth the price implies

-50%-25%0%+25%-50%0%68838245656005576887106051162005STAR000650603538002437PGHL.NSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Procter & Gamble Health is the large dot.

Procter & Gamble Health competitors and peer comparison

How Procter & Gamble Health compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Procter & Gamble Health against its 20 peers (data as of 18 Nov 2026)
MeasurePGHL.NSPeer medianRank in peer set
1-month return+7.2%-7.6%3rd highest of 21
6-month return+3.1%-14.5%6th highest of 21
Distance from 52-week high-21.1%-38.2%4th highest of 21
Revenue growth (TTM)+13.0%+5.7%8th highest of 19
Operating margin30.8%10.5%highest of 19
Forward P/E24.5×19.8×5th most expensive of 14
Growth the price implies (Req g, 7 yrs)5.6%7.0%6th least demanding of 13
Growth delivered (Del g)+9.3%+2.6%4th highest of 13
Hurdle (Req g minus delivered)-3.7 pp+1.8 pp4th least demanding of 13
ROIC minus cost of capital+86.5 pp-0.8 pphighest of 19
EV / EBITDA19.3×11.1×3rd most expensive of 6
Net debt / EBITDA-0.7×2.1×least indebted of 6

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Procter & Gamble Health PGHL.NSIndia$979M+3%+13%31%24.5×5.6%+9.3%
Seaport Therapeutics SPTXUnited States$980M+16%n/an/an/an/an/a
Chongqing Taiji Industry (Group) 600129.SSChina$982M-20%-4%2%69.8×n/an/a
InventisBio 688382.SSChina$982M-47%-61%-563%n/a6.5%-60.6%
Aarti Pharmalabs AARTIPHARM.NSIndia$984M+44%+13%18%n/an/an/a
Nxera Pharma 4565.TJapan$974M+46%+24%14%25.8×17.7%+27.3%
Jiangsu Kanion Pharmaceutical 600557.SSChina$989M-9%+8%7%19.8×2.3%+1.8%
BeBetter Med 688759.SSChina$960M-58%n/an/an/an/an/a
China Resources Boya Bio-pharmaceutical 300294.SZChina$959M-21%-27%-19%21.4×n/an/a
Shanghai InnoStar Bio-tech 688710.SSChina$1,000M+17%+24%6%59.3×12.7%+19.4%
Aurisco Pharmaceutical 605116.SSChina$1.00B-23%+3%25%13.6×-2.0%+18.7%
Shanghai Yizhong Pharmaceutical 688091.SSChina$1.00B-49%+32%14%n/an/an/a
SSY 2005.HKHong Kong$948M+8%-4%12%12.5×2.3%-0.5%
SAWAI 4887.TJapan$1.01B-18%+2%9%12.0×n/an/a
Strides Pharma Science STAR.NSIndia$946M-17%+11%14%15.9×17.6%+7.8%
Renhe Pharmacy 000650.SZChina$1.01B-12%-7%14%16.9×-10.7%-7.0%
Ningbo Menovo Pharmaceutical 603538.SSChina$945M-48%+19%9%42.3×11.6%+4.9%
Zhejiang Tianyu Pharmaceutical 300702.SZChina$1.02B+1%+27%4%21.4×4.3%+3.5%
Harbin Gloria Pharmaceuticals 002437.SZChina$941M-9%-16%13%n/a7.7%-6.9%
KPC Pharmaceuticals 600422.SSChina$940M-6%-41%-10%n/an/an/a
Jiangxi Fushine Pharmaceutical 300497.SZChina$1.02B-23%+103%24%9.9×7.5%-4.5%

Questions

Which companies are Procter & Gamble Health's closest peers?
The cockpit's peer set: Seaport Therapeutics (SPTX), Chongqing Taiji Industry (Group) (600129.SS), InventisBio (688382.SS), Aarti Pharmalabs (AARTIPHARM.NS), Nxera Pharma (4565.T), Jiangsu Kanion Pharmaceutical (600557.SS), BeBetter Med (688759.SS), China Resources Boya Bio-pharmaceutical (300294.SZ).
Is Procter & Gamble Health expensive compared with its peers?
On forward p/e it trades at 24.5× against a peer median of 19.8×, 5th most expensive of 14 in its peer set. For today's price to make sense, revenue must grow about 6% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is -4 pp: the price already allows for a slowdown.
How has Procter & Gamble Health stock performed?
Over six months to 18 Nov 2026 the shares returned +3.1% against -14.5% for the median peer; over one year -6.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.